This clinical trial is a pharmacokinetic (PK) study evaluating how the body handles a potential new chin-fat reduction treatment. PK studies are required by the FDA for all new drugs. The sponsor, Raziel Therapeutics, is planning to continue the clinical trial in China. China’s National Medical Products Administration (NMPA) requires that Raziel Therapeutics conducts this specific PK study evaluating drug tolerability in Chinese patients.
While the NMPA requires a certain number of participants to be Chinese, this clinical study is open to patients of all ethnicities, races, and nationalities. If you have additional questions, please contact us at email@example.com.
Sorry, no records were found. Please adjust your search criteria and try again.
Sorry, unable to load the Maps API.